Tvardi Therapeutics (TVRD) Stock Price, News & Analysis

Company Overview

Cara Therapeutics, Inc., an early commercial-stage biopharmaceutical company, focuses on developing and commercializing chemical entities with a primary focus on pruritus and pain by selectively targeting kappa opioid receptors in the United States. The company is developing product candidates that target the body's peripheral nervous system and immune cells. The company's lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis. Its product candidate includes Oral KORSUVA (difelikefalin), which has completed Phase II clinical trial to treat pruritus atopic dermatitis and pruritus non-dialysis-dependent chronic kidney disease (NDD-CKD) associated pruritus; and in Phase II clinical trial to treat pruritus chronic liver disease (CLD) primary biliary cholangitis (PBC) and notalgia paresthetica. The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea. Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.

Key Stats

• Today's Range: $27.52 to $29.93
• 50-Day Range: $21.45 to $29.83
• 52-Week Range: $8.13 to $34.31
• Volume: 21,325 shs
• Average Volume: 33,387 shs
• Market Capitalization: $274.18 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $64.25
• Consensus Rating: Buy

TVRD Stock Analysis - Frequently Asked Questions

How have TVRD shares performed this year?

Tvardi Therapeutics' stock was trading at $29.09 on January 1st, 2025. Since then, TVRD stock has decreased by 3.0% and is now trading at $28.22.

How were Tvardi Therapeutics' earnings last quarter?

Tvardi Therapeutics, Inc. (NASDAQ:TVRD) released its quarterly earnings data on Thursday, August, 14th. The company reported ($1.00) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by $0.49. Tvardi Therapeutics had a negative trailing twelve-month return on equity of 565.83% and a negative net margin of 678.79%.

Who are Tvardi Therapeutics' major shareholders?

Top institutional investors of Tvardi Therapeutics include Slate Path Capital LP (7.52%), 683 Capital Management LLC (1.88%), Geode Capital Management LLC (1.20%) and Marshall Wace LLP (0.27%).

How do I buy shares of Tvardi Therapeutics?

Shares of TVRD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 8/14/2025
• Today: 8/25/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:TVRD
• Previous Symbol: NASDAQ:TVRD
• CIK: 1346830
• Web: N/A
• Phone: (203) 406-3700
• Fax: 203-567-1510
• Employees: 80
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Tvardi Therapeutics: $64.25
• High Price Target: $78.00
• Low Price Target: $52.00
• Potential Upside/Downside: +129.5%
• Consensus Rating: Buy
• Rating Score (0-4): 3.00
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$70.87 million
• Net Margins: -678.79%
• Pretax Margin: -453.48%
• Return on Equity: -565.83%
• Return on Assets: -66.71%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.04
• Quick Ratio: 4.04

Sales & Book Value

• Annual Sales: $7.14 million
• Price / Sales: 36.78
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: ($3.02) per share
• Price / Book: -9.27

Miscellaneous

• Outstanding Shares: 9,380,000
• Free Float: 9,086,000
• Market Cap: $262.64 million
• Optionable: N/A
• Beta: 0.21